Cambridge Antibody, Molecular Partners to cross-license intellectual property

By Lisa Kerner

Charlotte, N.C., July 26 - Cambridge Antibody Technology (CAT) and Molecular Partners AG signed a cross-license agreement that gives the companies freedom to conduct research using each others' intellectual property, including the right to develop therapeutic, prophylactic and diagnostic products.

CAT obtains access to Molecular Partners proprietary Designed Repeat Proteins (DRPs) technology, while Molecular Partners gains rights to CAT-controlled intellectual property in ribosome display for novel protein products.

Molecular Partners can develop an unlimited number of Designed Repeat Protein products for biotechnological tests and reagents, diagnostic tests and reagents, and therapeutics. The company may also sublicense the ribosome display with the DRP technology to third parties.

CAT may develop and commercialize products using DRP technology, as well as sublicense products to collaboration partners.

CAT is a Cambridge, England-based biopharmaceutical company.

Molecular Partners is a biotechnology company located in Zurich, Switzerland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.